
\beginsupplement

# Supplement

|  **Condition**         | **mFcγRI**     | **mFcγRIIB**   | **mFcγRIII**     | **mFcγRIV**     | **Effectiveness** |
| ---------------------- | -------------- | -------------- | ---------------- | -------------- | ------------------ |
| **mIgG1**              | $0$            | $3\times 10^6$ | $3\times 10^5$   | $0$            | 0.00               |
| **mIgG2a**             | $1\times 10^8$ | $4\times 10^5$ | $7\times 10^5$   | $3\times 10^7$ | 0.95               |
| **mIgG2b**             | $1\times 10^5$ | $2\times 10^6$ | $6\times 10^5$   | $2\times 10^7$ | 0.20               |
| **mIgG3**              | $2\times 10^7$ | $0$            | $0$              | $0$            | 0.00               |
| **mIgG1-FcγRIIB-/-**   | $0$            | $0$            | $3\times 10^5$   | $0$            | 0.70               |
| **mIgG2a-FcγRIIB-/-**  | $1\times 10^8$ | $0$            | $7\times 10^5$   | $3\times 10^7$ | 1.00               |
| **mIgG2b-FcγRIIB-/-**  | $1\times 10^5$ | $0$            | $6\times 10^5$   | $2\times 10^7$ | 0.75               |
| **mIgG3-FcγRIIB-/-**   | $2\times 10^7$ | $0$            | $0$              | $0$            | 0.00               |
| **mIgG2a-FcγRI-/-**    | $0$            | $4\times 10^5$ | $7\times 10^5$   | $3\times 10^7$ | 0.80               |
| **mIgG2a-FcγRIII-/-**  | $1\times 10^8$ | $4\times 10^5$ | $0$              | $3\times 10^7$ | 0.93               |
| **mIgG2a-FcγRI,IV-/-** | $0$            | $4\times 10^5$ | $7\times 10^5$   | $0$            | 0.35               |
| **mIgG2b-Fucose-/-**   | $1\times 10^5$ | $1\times 10^7$ | $1.1\times 10^6$ | $2\times 10^8$ | 0.70               |

Table S1. **Murine knockout conditions and mFcγR-mIgG affinities.** Murine knockout conditions and mFcγR-mIgG affinities used in principal component analysis shown in [@Fig:InVivoResults]. Values in columns labeled with mFcγRs are affinities with M\textsuperscript{-1} units [@Gavin20; @Guilliams:2014cm]. Values in the effectiveness column represent proportional reduction in lung metastases observed with treatment [@Nimmerjahn:2005hu]. (E.g. A value of 0.0 means the number of lung metastases was unaffected, while 1.0 means they were all cleared.)


| **Antigen** | **Isotype** | **Clone** | **Provider** |
| ----------- | ----------- | --------- | ------------ |
| **CD11b**   | rat IgG2b   | M1/70     | AbD Serotec; BioLegend |
| **CD45**    | rat IgG2b   | 30-F11    | BD Biosciences, BioLegend |
| **CD62L**   | rat IgG2a   | MEL-14    | eBioscience, BioLegend |
| **Gr-1 (Ly6G/C)** | rat IgG2b | RB6-8C5 | BD Biosciences, BioLegend |
| **Ly6G**    | rat IgG2a   | 1A8       | BD Biosciences, BioLegend |
| **NK1.1**   | mouse IgG2a | PK136     | Southern Biotech; Biolegend |
| **FcγR1 (CD64)** | mouse IgG1 | X54-5/7.1 | BD Biosciences |
| **FcγR2b (CD32b)** | mouse IgG2a | Ly17.2 | In-house |
| **FcγR3 (CD16)** | rat IgG2a | 275003 | R&amp;D Systems Europe |
| **FcγR4**   | Arm. hamster | 9E9      | In-house; Biolegend |

Table S2. **Antibodies for cell identification and mFcγR quantitation.**


![**Parameter autocorrelation for each parameter and each walker.** Solid and dotted lines indicate the 95th and 99th percentile significance bounds.](./Figures/FigureAA.svg){#fig:Autocorrel}

![**Supplementary results to *in vivo* predictions.** A) Receptor abundance quantified across different peripheral immune cell populations. Error bars indicate standard error of biological replicates (N >= 3). B) Prediction performance upon crossvalidation for the model predicting *in vivo* efficacy with differing assumed IC concentration and avidity.](./Figures/FigureS2.svg){#fig:SuppTwo}
